drugset
drugset / Trial / NCT04762407

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903

NCT04762407 ↗

Phase 1 Completed 57 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of HCP1903 in healthy subjects.

Timeline

Start
2020-11-20
Primary completion
2021-02-24
Completion
2021-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1903 Unknown — —
Subject HGP1909 Unknown — —
Subject HGP1910 Unknown — —

Indications

No indication recorded.